TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient

Annals of Pharmacotherapy

Volumn 45, Issue 7-8, 2011, Pages

  Pea, Federico ^a,b   Cojutti, Piergiorgio ^a,b   Sbrojavacca, Rodolfo ^a   Cadeo, Barbara ^a,c   Cristini, Francesco ^a,c   Bulfoni, Alessandro ^a   Furlanut, Mario ^a,b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

Cellulitis; Daptomycin; Meropenem; Serum creatine kinase; Therapeutic drug monitoring

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; DAPTOMYCIN; GLUCOSE; HEMOGLOBIN; LEVOFLOXACIN; MEROPENEM; SODIUM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ACCURACY; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; BLOOD PRESSURE; BODY MASS; BODY TEMPERATURE; BREATHING RATE; CARBON DIOXIDE TENSION; CASE REPORT; CELLULITIS; CONTINUOUS INFUSION; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG ISOLATION; DRUG MEGADOSE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY WARD; ERYTHEMA; GLUCOSE BLOOD LEVEL; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; LEG ULCER; LEUKOCYTE COUNT; LIMIT OF DETECTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NECROTIZING FASCIITIS; OBESITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SODIUM BLOOD LEVEL; STEADY STATE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; BLOOD; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED; MORBID OBESITY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CELLULITIS; CREATINE KINASE; DAPTOMYCIN; DRUG MONITORING; DRUG THERAPY, COMBINATION; FASCIITIS, NECROTIZING; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; THIENAMYCINS; TREATMENT OUTCOME;

EID: 79960797975     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P745     Document Type: Article

References (20)

1. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004;32:1535-41.
2. Mendez AS, Steppe M, Schapoval EE. Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Pharm Biomed Anal 2003;33:947-54.
3. Martens-Lobenhoffer J, Kielstein JT, Oye C, Bode-Boger SM. Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008;875:546-50.
4. Polillo M, Tascini C, Lastella M, et al. A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit 2010;32:200-5.
5. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010;50:1568-74.
6. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406.
7. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007;27:1081-91.
8. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009;64:142-50.
9. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimi-crob Agents Chemother 2007;51:1725-30.
10. Begic D, von Eiff C, Tsuji BT. Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype. J Antimicrob Chemother 2009;63:977-81.
11. The European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints 2011. www.eucast.org/clinical_breakpoints (accessed 2011 Feb 11).
12. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005;45:48-56.
13. Wada DR, Drover DR, Lemmens HJ. Determination of the distribution volume that can be used to calculate the intravenous loading dose. Clin Pharmacokinet 1998;35:1-7.
14. Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 2008;62(suppl 3):15-23.
15. Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD. Rapid bactericidal activity of daptomycin against methicillin-resistant and me-thicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007;51:1787-94.
16. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necro-tizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003;85-A:1454-60.
17. Simonart T, Simonart JM, Derdelinckx I, et al. Value of standard laboratory tests for the early recognition of group A beta-hemolytic streptococ-cal necrotizing fasciitis. Clin Infect Dis 2001;32:E9-12.
18. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau D P. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011;37:632-8.
19. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010;65:1073-5.
20. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009;66:642-8.